Compugen And Merck Serono To Collaborate On Novel Peptide For The Treatment Of Inflammatory Diseases

Compugen Ltd. (NASDAQ:CGEN) announced today that it has signed a collaboration agreement with Merck KGaA, acting for its pharmaceutical division Merck Serono, covering CGEN-855, a Compugen-discovered novel peptide targeting the FPRL1 G-protein coupled receptor (GPCR). This peptide has demonstrated, in recently completed initial in vitro and in vivo studies, the potential to treat, among other indications, inflammatory diseases.

More: continued here

Filed under: Pharma Industry on December 2nd, 2008